Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples

Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.

Investors Business Daily

Medicare review: what changes can we expect to see - and what’s still missing?

Health sector welcomes the broad vision of taskforce report, but worries it’s short on details, a timeline and money

The Guardian - AU

Australia to allow prescription of MDMA and psilocybin for treatment-resistant mental illnesses

From July, authorised psychiatrists will be able to prescribe the drugs for post-traumatic stress disorder and severe depression

The Guardian - AU

From analysis to the latest developments in health,
read the most diverse news in one place.

Restrictions flagged on bulk paracetamol sales

An interim decision by the medicines regulator would prevent Australians from buying packs of up to 100 paracetamol tablets without speaking to a pharmacist.

AAP

Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years

Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped.

Investors Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Investors Business Daily

Eye drops linked to US drug-resistant bacteria outbreak

U.S. health officials are advising people to stop using over-the-counter eye drops that have been linked to an outbreak of drug-resistant infections

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks to Buy in 2023 and Hold for Decades

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

StockNews.com

Merck Lands In Hot Water After 2023 Profit Guidance Widely Misses Forecasts

Merck's profit guidance for 2023 widely missed Wall Street's projections on Thursday, leading Merck stock to crumble despite a quarterly beat.

Investors Business Daily

Eli Lilly Dives After A 'Bump In The Road' Shakes Its Newest Diabetes Drug

Eli Lilly experienced a "bump in the road" for its newest diabetes treatment, Mounjaro, an analyst said Thursday as LLY stock toppled.

Investors Business Daily

Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming

Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.

Investors Business Daily

Eli Lilly Tops Q4 Earnings Forecast, Lifts 2023 Outlook, On Trulicity Strength

"Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3." said CEO David Ricks.

The Street

Merck Stock Slumps As 2023 Profit Outlook Clouds Q4 Earnings Beat

Merck said it sees 2023 sales in the region of $57.2 billion and $58.7 billion.

The Street

Texas biotech company, UT win $42 million patent case against Boston Scientific

A small Dallas biotech company and the University of Texas took on big pharma and won.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

The New Daily

Watch: NT alcohol restrictions report, Pharmacy prescribing

Watch: The funeral for controversial Cardinal George Pell is underway. An urgent report into alcohol restrictions in Alice Springs is expected to

Tribune News Service

Merck COVID drug linked to new virus mutations, study says

Merck & Co.’s COVID-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

Los Angeles Times

DC boss James Gunn shrugs off 'Shazam' star Zachary Levi's anti-Pfizer tweet

DC boss James Gunn has addressed a controversial tweet from Zachary Levi that called into question the "Shazam!" star's position on vaccines.

The Street

Jim Cramer Gushes Over Pharmaceutical Stock's Chart: 'About The Greatest You've Ever Seen'

CNBC's Jim Cramer has a lot to say about Wegovy, Novo Nordisk's fast-selling weight loss treatment.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

GSK boss warns UK life sciences at ‘tipping point’ despite Sunak’s R&D pledge

Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas

StockNews.com

3 Biotech Stocks to Get in on Before It’s Too Late

Rapidly growing market for personalized medicines and revolutionary technologies like 3D bioprinting is expected to bolster the biotech industry. Moreover, rising government initiatives should support its growth. Hence, quality biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal buys. Continue reading.

Investors Business Daily

Prime-Time Battles Drive GSK And Novo Nordisk In 2023; Novartis Preps Its Spinoff

GSK stock and NVO stock rose Wednesday, though both beat forecasts. Novartis stock skidded on lighter-than-expected sales.

Bangkok Post

Tougher 'intent to supply' meth law to go ahead

The Ministry of Public Health will press ahead with a controversial amendment that would make possession of more than one methamphetamine pill dealing in illegal narcotics.

Bangkok Post

Hong Kong bans CBD, with stiff penalties

 A new law criminalising the possession, consumption and selling of cannabidiol (CBD) in Hong Kong came into effect on Wednesday, placing the substance on par with heroin in terms of legal classification.

AFP

Hong Kong bans CBD, ranking it alongside heroin and cocaine

Hong Kong (AFP) - A new law criminalising the possession, consumption and selling of cannabidiol (CBD) in Hong Kong came into effect on Wednesday, placing the substance on par with heroin in terms of legal classification.

WEKU

Hong Kong bans CBD, a move that forces businesses to shut down or revamp

Hong Kong banned cannibidiol, also known as CBD, as a "dangerous drug" and imposed harsh penalties for possession on Wednesday, forcing fledging businesses to shut down and revamp.

1 … 47 48 49 50

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.